Which has stronger earnings & valuation, VRX or MRV?

Nuvo Pharmaceuticals has higher revenue and earnings than Valeant Pharmaceuticals International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valeant Pharmaceuticals International N/A N/A N/A N/A N/A Nuvo Pharmaceuticals C$8.72B 4.55 C$15.17M C$2.91 15.57

Which has higher valuation & earnings, MRV or APHA?

Nuvo Pharmaceuticals has higher revenue and earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvo Pharmaceuticals C$8.72B 4.55 C$15.17M C$2.91 15.57 Aphria C$611.06M 0.00 -C$637.39M -C$2.01 N/A

Do analysts prefer MRV or BHC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bausch Health Companies 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer CRON or MRV?

Cronos Group currently has a consensus target price of C$4.75, indicating a potential upside of 22.74%. Given Cronos Group's stronger consensus rating and higher probable upside, research analysts clearly believe Cronos Group is more favorable than Nuvo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Nuvo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, CRON or MRV?

Nuvo Pharmaceuticals has higher revenue and earnings than Cronos Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cronos Group C$159.54M 9.06 -C$32.78M N/A N/A Nuvo Pharmaceuticals C$8.72B 4.55 C$15.17M C$2.91 15.57

Do analysts prefer DHT.UN or MRV?

DRI Healthcare Trust presently has a consensus price target of C$25.50, indicating a potential upside of 46.64%. Given DRI Healthcare Trust's stronger consensus rating and higher probable upside, research analysts plainly believe DRI Healthcare Trust is more favorable than Nuvo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DRI Healthcare Trust 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Nuvo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Nuvo Pharmaceuticals (MRV) Competitors

C$45.32 -0.17 (-0.37%)

As of 06/24/2026 03:59 PM Eastern

Compare

MRV vs. VRX, APHA, BHC, CRON, and DHT.UN

Should you buy Nuvo Pharmaceuticals stock or one of its competitors? MarketBeat compares Nuvo Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvo Pharmaceuticals include Valeant Pharmaceuticals International (VRX), Aphria (APHA), Bausch Health Companies (BHC), Cronos Group (CRON), and DRI Healthcare Trust (DHT.UN). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Nuvo Pharmaceuticals compare to Valeant Pharmaceuticals International?

Valeant Pharmaceuticals International (TSE:VRX) and Nuvo Pharmaceuticals (TSE:MRV) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Valeant Pharmaceuticals International's average media sentiment score of 0.00 equaled Nuvo Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Valeant Pharmaceuticals International	Neutral
Nuvo Pharmaceuticals	Neutral

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Valeant Pharmaceuticals International's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Valeant Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valeant Pharmaceuticals International	N/A	N/A	N/A
Nuvo Pharmaceuticals	20.95%	1,180.47%	5.85%

Nuvo Pharmaceuticals has higher revenue and earnings than Valeant Pharmaceuticals International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valeant Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
Nuvo Pharmaceuticals	C$8.72B	4.55	C$15.17M	C$2.91	15.57

Summary

Nuvo Pharmaceuticals beats Valeant Pharmaceuticals International on 6 of the 6 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Aphria?

Nuvo Pharmaceuticals (TSE:MRV) and Aphria (TSE:APHA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

In the previous week, Nuvo Pharmaceuticals' average media sentiment score of 0.00 equaled Aphria'saverage media sentiment score.

Company	Overall Sentiment
Nuvo Pharmaceuticals	Neutral
Aphria	Neutral

1.8% of Nuvo Pharmaceuticals shares are owned by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Aphria's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Aphria's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvo Pharmaceuticals	20.95%	1,180.47%	5.85%
Aphria	N/A	N/A	N/A

Nuvo Pharmaceuticals has higher revenue and earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvo Pharmaceuticals	C$8.72B	4.55	C$15.17M	C$2.91	15.57
Aphria	C$611.06M	0.00	-C$637.39M	-C$2.01	N/A

Summary

Nuvo Pharmaceuticals beats Aphria on 9 of the 9 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Bausch Health Companies?

Nuvo Pharmaceuticals (TSE:MRV) and Bausch Health Companies (TSE:BHC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Nuvo Pharmaceuticals has higher earnings, but lower revenue than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvo Pharmaceuticals	C$8.72B	4.55	C$15.17M	C$2.91	15.57
Bausch Health Companies	C$10.53B	0.25	-C$125.65M	-C$3.24	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvo Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bausch Health Companies	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nuvo Pharmaceuticals has a beta of 0.917796, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Bausch Health Companies has a beta of 0.942978, meaning that its stock price is 6% less volatile than the broader market.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Bausch Health Companies' net margin of -13.54%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Bausch Health Companies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvo Pharmaceuticals	20.95%	1,180.47%	5.85%
Bausch Health Companies	-13.54%	120.43%	4.16%

1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. Comparatively, 11.1% of Bausch Health Companies shares are held by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are held by company insiders. Comparatively, 11.3% of Bausch Health Companies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Nuvo Pharmaceuticals' average media sentiment score of 0.00 equaled Bausch Health Companies'average media sentiment score.

Company	Overall Sentiment
Nuvo Pharmaceuticals	Neutral
Bausch Health Companies	Neutral

Summary

Nuvo Pharmaceuticals beats Bausch Health Companies on 7 of the 12 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Cronos Group?

Cronos Group (TSE:CRON) and Nuvo Pharmaceuticals (TSE:MRV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

In the previous week, Cronos Group had 1 more articles in the media than Nuvo Pharmaceuticals. MarketBeat recorded 1 mentions for Cronos Group and 0 mentions for Nuvo Pharmaceuticals. Cronos Group's average media sentiment score of 0.00 equaled Nuvo Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Cronos Group	Neutral
Nuvo Pharmaceuticals	Neutral

4.6% of Cronos Group shares are owned by institutional investors. Comparatively, 1.8% of Nuvo Pharmaceuticals shares are owned by institutional investors. 46.4% of Cronos Group shares are owned by company insiders. Comparatively, 6.3% of Nuvo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cronos Group has a beta of 1.134248, indicating that its share price is 13% more volatile than the broader market. Comparatively, Nuvo Pharmaceuticals has a beta of 0.917796, indicating that its share price is 8% less volatile than the broader market.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Cronos Group's net margin of -1.29%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-1.29%	-0.19%	-3.73%
Nuvo Pharmaceuticals	20.95%	1,180.47%	5.85%

Cronos Group currently has a consensus target price of C$4.75, indicating a potential upside of 22.74%. Given Cronos Group's stronger consensus rating and higher probable upside, research analysts clearly believe Cronos Group is more favorable than Nuvo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Nuvo Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Nuvo Pharmaceuticals has higher revenue and earnings than Cronos Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	C$159.54M	9.06	-C$32.78M	N/A	N/A
Nuvo Pharmaceuticals	C$8.72B	4.55	C$15.17M	C$2.91	15.57

Summary

Cronos Group beats Nuvo Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to DRI Healthcare Trust?

DRI Healthcare Trust (TSE:DHT.UN) and Nuvo Pharmaceuticals (TSE:MRV) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

0.6% of DRI Healthcare Trust shares are owned by institutional investors. Comparatively, 1.8% of Nuvo Pharmaceuticals shares are owned by institutional investors. 0.1% of DRI Healthcare Trust shares are owned by insiders. Comparatively, 6.3% of Nuvo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

DRI Healthcare Trust presently has a consensus price target of C$25.50, indicating a potential upside of 46.64%. Given DRI Healthcare Trust's stronger consensus rating and higher probable upside, research analysts plainly believe DRI Healthcare Trust is more favorable than Nuvo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DRI Healthcare Trust	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Nuvo Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

DRI Healthcare Trust has a beta of 0.472401, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Nuvo Pharmaceuticals has a beta of 0.917796, indicating that its stock price is 8% less volatile than the broader market.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to DRI Healthcare Trust's net margin of 5.02%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat DRI Healthcare Trust's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DRI Healthcare Trust	5.02%	2.06%	4.22%
Nuvo Pharmaceuticals	20.95%	1,180.47%	5.85%

Nuvo Pharmaceuticals has higher revenue and earnings than DRI Healthcare Trust. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DRI Healthcare Trust	C$163.77M	5.84	C$9.73M	-C$0.90	N/A
Nuvo Pharmaceuticals	C$8.72B	4.55	C$15.17M	C$2.91	15.57

In the previous week, DRI Healthcare Trust's average media sentiment score of 0.00 equaled Nuvo Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
DRI Healthcare Trust	Neutral
Nuvo Pharmaceuticals	Neutral

Summary

Nuvo Pharmaceuticals beats DRI Healthcare Trust on 10 of the 14 factors compared between the two stocks.

Get Nuvo Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

MRV vs. The Competition

Export

Metric	Nuvo Pharmaceuticals	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$345.64B	C$7.19B	C$6.74B	C$12.98B
Dividend Yield	N/A	2.95%	2.68%	6.19%
P/E Ratio	15.57	5.01	25.14	35.22
Price / Sales	4.55	1,651.70	531.12	10.20
Price / Cash	0.23	10.18	45.29	82.29
Price / Book	60.43	10.88	10.77	4.38
Net Income	C$15.17M	C$20.27B	C$3.56B	C$299.09M
7 Day Performance	-10.52%	-0.24%	1.00%	-2.11%
1 Month Performance	32.98%	-1.12%	0.81%	-3.38%
1 Year Performance	N/A	11.41%	30.27%	37.21%

Nuvo Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
MRV Nuvo Pharmaceuticals	N/A	C$45.32 -0.4%	N/A	N/A	C$345.64B	C$8.72B	15.57	N/A
VRX Valeant Pharmaceuticals International	N/A	N/A	N/A	N/A	C$10.76B	N/A	N/A	N/A
APHA Aphria	N/A	N/A	N/A	N/A	C$5.24B	C$611.06M	N/A	1,200
BHC Bausch Health Companies	0.2592 of 5 stars	C$6.74 +0.3%	N/A	-16.3%	C$2.52B	C$10.53B	N/A	19,900
CRON Cronos Group	1.9675 of 5 stars	C$3.85 +2.4%	C$4.75 +23.4%	+48.8%	C$1.44B	C$159.54M	N/A	450

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:MRV) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvo Pharmaceuticals (MRV) Competitors

MRV vs. VRX, APHA, BHC, CRON, and DHT.UN

How does Nuvo Pharmaceuticals compare to Valeant Pharmaceuticals International?

Summary

How does Nuvo Pharmaceuticals compare to Aphria?

Summary

How does Nuvo Pharmaceuticals compare to Bausch Health Companies?

Summary

How does Nuvo Pharmaceuticals compare to Cronos Group?

Summary

How does Nuvo Pharmaceuticals compare to DRI Healthcare Trust?

Summary

New MarketBeat Followers Over Time

MRV vs. The Competition

Nuvo Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvo Pharmaceuticals (MRV) Competitors

MRV vs. VRX, APHA, BHC, CRON, and DHT.UN

How does Nuvo Pharmaceuticals compare to Valeant Pharmaceuticals International?

Do institutionals and insiders have more ownership in VRX or MRV?

Does the media favor VRX or MRV?

Is VRX or MRV more profitable?

Which has stronger earnings & valuation, VRX or MRV?

Summary

How does Nuvo Pharmaceuticals compare to Aphria?

Does the media refer more to MRV or APHA?

Do institutionals and insiders believe in MRV or APHA?

Is MRV or APHA more profitable?

Which has higher valuation & earnings, MRV or APHA?

Summary

How does Nuvo Pharmaceuticals compare to Bausch Health Companies?

Which has higher earnings and valuation, MRV or BHC?

Do analysts prefer MRV or BHC?

Which has more risk & volatility, MRV or BHC?

Is MRV or BHC more profitable?

Do institutionals & insiders believe in MRV or BHC?

Does the media refer more to MRV or BHC?

Summary

How does Nuvo Pharmaceuticals compare to Cronos Group?

Does the media prefer CRON or MRV?

Do insiders & institutionals have more ownership in CRON or MRV?

Which has more volatility & risk, CRON or MRV?

Is CRON or MRV more profitable?

Do analysts prefer CRON or MRV?

Which has better earnings & valuation, CRON or MRV?

Summary

How does Nuvo Pharmaceuticals compare to DRI Healthcare Trust?

Do institutionals and insiders have more ownership in DHT.UN or MRV?

Do analysts prefer DHT.UN or MRV?

Which has more risk and volatility, DHT.UN or MRV?

Is DHT.UN or MRV more profitable?

Which has higher valuation & earnings, DHT.UN or MRV?

Does the media prefer DHT.UN or MRV?

Summary

New MarketBeat Followers Over Time

MRV vs. The Competition

Nuvo Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools